Diabetes

A rising healthcare concern, a growing therapeutic space

Diabetes is a significant healthcare concern in Malaysia and its threat continues to grow among the population.

1 in 5 adults

in Malaysia have diabetes, equivalent to about 3.9 million people aged 18 years and above.

The National Health and Morbidity Survey (NHMS) 20191

Diabetes Rising

Data from the National Health and Morbidity Survey over the years shows a steadily rising prevalence of diabetes – among those diagnosed with the disease as well as undiagnosed Malaysians who have raised blood glucose.2
Reported using
insulin therapy
27.5%
Reported using
oral antidiabetic drugs
85.6%
Reported receiving specific diabetes diet advice
from healthcare personnel
88%
Reported receiving advice
to lose weight from healthcare personnel
75.4%
Reported seeking treatment primarily
at public primary care facilities
74.3%
Reported opting for traditional and
complementary medication
23%
patients with diabetes

1.7 million

As of 2020, there was a total of 1,698,683 patients enrolled in the National Diabetes Registry, with 902,991 being active patients who had visited a health clinic at least once in the past year. 3

type 2 diabetes

>99%

Almost all (99.33%) registered patients had been diagnosed with Type 2 Diabetes. The majority were between 55-59 years old (16.59%) and the mean age at diagnosis was 53 years old.

co-morbidities

Risk

The vast majority of patients also had common co-morbidities, particularly hypertension (80%) and dyslipidaemia (75.72%).

ethical

Pharmaceuticals

Most patients were on common oral anti-diabetic drugs such as metformin (84.30%) and sulphonylureas (44.60%), while 30.02% were treated with insulin.

Our Therapies

There is a clear demand for effective medicines that can help Malaysians with diabetes control their disease for better quality of life. Among our portfolio of classic and specialty pharmaceutical drugs for the domestic and international market are generic drugs and biosimilar products to treat prevalent diseases such as diabetes.

Our specialty portfolio includes biosimilar insulin therapies for diabetes including Insugen and Basalog One.

INSUPen Pro reusable injectable pen devices are designed for use exclusively with the Insugen range of insulins.

References

  1. Institute for Public Health 2020. National Health and Morbidity Survey (NHMS) 2019, Non-communicable diseases, healthcare demand, and health literacy—Key Findings
  2. Institute for Public Health (IPH), National Institutes of Health, Ministry of Health Malaysia. 2020. National Health and Morbidity Survey (NHMS) 2019: Vol. I: NCDs – Non-Communicable Diseases: Risk Factors and other Health Problems
  3. Ministry of Health Malaysia. 2021. National Diabetes Registry Report 2020